BioMarin Pharmaceutical Inc. Stock News

While the company broadly met expectations for the fourth quarter, investors seemed concerned about its 2022 guidance.

Biomarin Pharmaceutical's (BMRN) fourth-quarter earnings and sales beat estimates. Stock declines

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (NASDAQ: ADGI) announced th

Biomarin Pharmaceutical's (BMRN) fourth-quarter earnings and sales beat estimates. Stock declines

BioMarin Pharmaceutical Inc (NASDAQ: BMRN ) reported a 1% Y/Y decrease in Q4 revenue to $449.8 million , beating the consensus estimate of $442.39 million. The decline was attributable to lower sales from Kuvan and Naglazyme, cushioned by higher revenues from Aldurazyme, Vimizim, and Palynziq. Kuvan sales decreased 23% to $ 68.5 million, primarily due to generic competition. Lower Naglazyme product revenues declined 31% to $83.1 million, primarily driven by … Full story available on Benzinga.com

BioMarin (BMRN) delivered earnings and revenue surprises of 250% and 1.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Biomarin Pharma Earnings, Revenue Beat in Q4

BioMarin Pharmaceutical Inc. (BMRN) CEO J.J. Bienaime on Q4 2021 Results - Earnings Call Transcript

BioMarin Pharmaceutical press release (BMRN): Q4 GAAP EPS of -$0.32 beats by $0.02.Revenue of $449.8M (-0.5% Y/Y) beats by $7.42M.For FY2022, the company expects revenue between…

- Full-year 2021 Total Revenues of $1.85 Billion; Revenues Excluding Kuvan Increased 11% Year-Over-Year

BioMarin (BMRN) delivered earnings and revenue surprises of 250% and 1.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study Kodiak Sciences

BioMarin Pharmaceutical (NASDAQ:BMRN) is scheduled to announce Q4 earnings results on Wednesday, Feb. 23, after market close.The consensus EPS estimate is -$0.01

Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.